AbbVie has been staging a generational handoff for years: as Humira’s U.S. exclusivity fell and biosimilars swarmed, the company groomed Rinvoq and Skyrizi as the next standard-bearers. Investors already know the script: AbbVie has guided the duo to more than $31 billion in combined sales by 2027, and Humira’s 2022 global peak north of $21… The post AbbVie’s RINVOQ showed superiority over HUMIRA in rheumatoid arthritis study appeared first on Drug Discovery and Development.
